Causes of death on BsAb or CAR-T trials
| Agent . | N . | Median follow-up for assessing deaths (months) . | Available descriptions of deaths . |
|---|---|---|---|
| Mosunetuzumab | 90 | 18.3 | 8 deaths: 6 progressive FL and 2 other causes |
| Epcoritamab | 128 | 17.4 | 13 deaths: 6 COVID-19 infection, 7 other causes; deaths due to progressive FL not reported |
| Odronextamab | 128 | 26.6 | 19 deaths: 8 COVID-19 infection, 4 non-COVID-19 pneumonia, 1 PML, 1 Escherichia sepsis |
| Axicabtagene-ciloleucel | 127 | 41.7 | 32 deaths: 10 progressive FL, 10 infectious causes, 5 other malignancies, 7 other causes |
| Tisagenlecleucel | 97 | 28.9 | 13 deaths: 7 progressive FL, 1 PML, 1 hemophagocytic lymphohistiocytosis, 4 other causes; all >30 days after infusion |
| Lisocabtagene-maraleucel | 130 | 17.9 | 12 deaths postinfusion: 4 progressive FL, 1 macrophage-activation syndrome, 1 PML, 6 other causes |
| Agent . | N . | Median follow-up for assessing deaths (months) . | Available descriptions of deaths . |
|---|---|---|---|
| Mosunetuzumab | 90 | 18.3 | 8 deaths: 6 progressive FL and 2 other causes |
| Epcoritamab | 128 | 17.4 | 13 deaths: 6 COVID-19 infection, 7 other causes; deaths due to progressive FL not reported |
| Odronextamab | 128 | 26.6 | 19 deaths: 8 COVID-19 infection, 4 non-COVID-19 pneumonia, 1 PML, 1 Escherichia sepsis |
| Axicabtagene-ciloleucel | 127 | 41.7 | 32 deaths: 10 progressive FL, 10 infectious causes, 5 other malignancies, 7 other causes |
| Tisagenlecleucel | 97 | 28.9 | 13 deaths: 7 progressive FL, 1 PML, 1 hemophagocytic lymphohistiocytosis, 4 other causes; all >30 days after infusion |
| Lisocabtagene-maraleucel | 130 | 17.9 | 12 deaths postinfusion: 4 progressive FL, 1 macrophage-activation syndrome, 1 PML, 6 other causes |